For instance, studies confirm that EZH2 possesses tumorigenic properties in lymphomas (Van Kemenade et al., 2001), chronic myelogenous leukemia (CML) (Xie et al., 2016), multiple myeloma (Xu et al., 2023), natural killer/T-cell lymphoma (NKTL) (Yan et al., 2013) as well as AML. This evidence concerns the gene SCYL1 and chronic myelogenous leukemia, BCR-ABL1 positive.